Efficacy and safety of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase II study in patients with breast cancer receiving myelosuppressive chemotherapy.

Olga V. Salafet,Tatiana V. Chernovskaya,Ludmila P. Sheveleva,Andrey V. Khorinko,Tatiana I. Prokopenko,Marina Nechaeva,Olga Burdaeva,Marina Matrosova,Nadezhda Kovalenko,Elena G. Ovchinnikova,Irina Koroleva,R. Ivanov

Efficacy and safety of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase II study in patients with breast cancer receiving myelosuppressive chemotherapy.

2013

Olga V. Salafet
Tatiana V. Chernovskaya
Ludmila P. Sheveleva
Andrey V. Khorinko
Tatiana I. Prokopenko
Marina Nechaeva
Olga Burdaeva
Marina Matrosova
Nadezhda Kovalenko
Elena G. Ovchinnikova
Irina Koroleva
R. Ivanov

e20593 Background: Pegfilgrastim (conjugate of filgrastim and 20 kDa polyethylene glycol (PEG) is approved for treatment of chemotherapy-associated neutropenia. BCD-017 (empegfilgrastim) is a coval...

Keywords:

Filgrastim
Oncology
Breast cancer
Myelosuppressive Chemotherapy
Phases of clinical research
Internal medicine
Medicine
PEG ratio
Pathology
Neutropenia
Polyethylene glycol
Pegfilgrastim

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations